Skip to search formSkip to main contentSkip to account menu

recurrent ovarian epithelial cancer

Known as: Recurrent Carcinoma of Ovary, ovarian carcinoma, recurrent, ovarian cancer recurrent 
The reemergence of ovarian carcinoma after a period of remission.
National Institutes of Health

Related topics

Related topics

11 relations
Endometrial CarcinomaEpithelial CellsEpitheliumFemale Reproductive System

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Highly Cited
2012
Highly Cited
2012
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1…
PURPOSE Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or… 
Review
2010
Review
2010
Maximal cytoreductive effort in epithelial ovarian cancer surgery.
The surgical management of advanced epithelial ovarian cancer involves cytoreduction, or removal of grossly-evident tumor… 
Highly Cited
2008
Highly Cited
2008
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
PURPOSE We aimed at investigating the efficacy, tolerability, and quality of life (QOL) of gemcitabine (GEM) compared with… 
Review
2006
Review
2006
Systemic therapy for ovarian cancer: current status and new treatments.
Current systemic therapy for ovarian cancer consists of a combination of carboplatin and paclitaxel. While the majority of… 
Highly Cited
2006
Highly Cited
2006
Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer
Purpose: One of the major obstacles in the treatment of ovarian cancer is the development of multidrug resistance. Recent… 
Review
2002
Review
2002
Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
Advances in the treatment and early detection of ovarian cancer have led to gains in 5-year survival rates, with 52% of women… 
Highly Cited
2001
Highly Cited
2001
Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.
PURPOSE The value of palliative chemotherapy in women with refractory and recurrent ovarian cancer is difficult to quantify, and… 
Highly Cited
1997
Highly Cited
1997
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
PURPOSE Paclitaxel has shown significant activity in advanced ovarian cancer. In vitro studies with paclitaxel have suggested… 
Highly Cited
1989
Highly Cited
1989
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.
A series of 33 patients were treated with a four-day continuous infusion of carboplatin in a phase I study to determine the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)